1. Wagner, L . Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther 1931; 8: 1931–1939.
Google Scholar2. Topatana, W, Juengpanich, S, Li, S, et al. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol 2020; 13: 118.
Google Scholar | Crossref | Medline3. National Center for Biotechnology Information . Pubchem compound summary for CID 11960529, veliparib. https://pubchem.ncbi.nlm.nih.gov/compound/Veliparib (Accessed 6 November, 2021).
Google Scholar4. Okuma, H, Yonemori, K. BRCA Gene mutations and poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Adv Exp Med Biol 2017; 1026: 271–286.
Google Scholar | Crossref | Medline5. Werner, T, Sachdev, J, Swisher, E, et al. Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer Med 2018; 7: 2360–2369.
Google Scholar | Crossref | Medline6. Li, X, Delzer, J, Voorman, R, et al. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos 2011; 39: 1161–1169.
Google Scholar | Crossref | Medline7. Nuthalapati, S, Munasinghe, W, Giranda, V, et al. Clinical pharmacokinetics and mass balance of veliparib in combination with temozolomide in subjects with nonhematologic malignancies. Clin Pharmacokinet 2017; 57: 51–58.
Google Scholar | Crossref8. Farmer, H, McCabe, N, Lord, C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917–921.
Google Scholar | Crossref | Medline | ISI9. Bryant, H, Schultz, N, Thomas, H, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913–917.
Google Scholar | Crossref | Medline | ISI10. Murai, J, Huang, S, Das, B, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588–5599.
Google Scholar | Crossref | Medline | ISI11. Patel, A, Sarkaria, J, Kaufmann, S. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011; 108: 3406–3411.
Google Scholar | Crossref | Medline | ISI12. Nieborowska-Skorska, M, Sullivan, K, Dasgupta, Y, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest 2017; 127: 2392–2406.
Google Scholar | Crossref | Medline13. Meng, X, Koh, B, Zhang, J, et al. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem 2014; 289: 20543–20558.
Google Scholar | Crossref | Medline14. Faraoni, I, Aloisio, F, De Gabrieli, A, et al. The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation. Cancer Lett 2018; 423: 127–138.
Google Scholar | Crossref | Medline15. Li, M, Yu, X. Function of BRCA1 in the DNA damage response Is mediated by ADP-ribosylation. Cancer Cell 2013; 23: 693–704.
Google Scholar | Crossref | Medline | ISI16. Boussios, S, Karihtala, P, Moschetta, M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs 2019; 38: 181–193.
Google Scholar | Crossref | Medline17. Kummar, S, Oza, A, Fleming, G, et al. Randomised trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res 2015; 21: 1574–1582.
Google Scholar | Crossref | Medline | ISI18. Coleman, R, Sill, M, Aghajanian, C, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a gynecologic oncology group study. Gynecol Oncol 2014; 133: 56–57.
Google Scholar | Medline19. Landrum, L, Brady, W, Armstrong, D, et al. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a gynecologic oncology group study. Gynecol Oncol 2015; 137: 23.
Google Scholar | Crossref | Medline20. Steffensen, K, Adimi, P, Jakobsen, A. Veliparib monotherapy to patients with BRCA germline mutation and platinum-resistant or partially platinum-sensitive selapse of epithelial ovarian cancer: a phase I/II study. J Clin Oncol 2016; 34: 5532–5532.
Google Scholar | Crossref21. Munasinghe, W, Stodtmann, S, Tolcher, A, et al. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomised, placebo-controlled crossover study. Cancer Chemother Pharmacol 2016; 78: 1003–1011.
Google Scholar | Crossref | Medline22. Reiss, K, Herman, J, Zahurak, M, et al. Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. J Clin Oncol 2016; 34: 2584–2584.
Google Scholar23. Nishikawa, T, Matsumoto, K, Tamura, K, et al. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci 2017; 108: 1834–1842.
Google Scholar | Crossref | Medline24. Nishio, S, Takekuma, M, Takeuchi, S, et al. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Sci 2017; 108: 2213–2220.
Google Scholar | Crossref | Medline25. Hjortkjær, M, Kanstrup, H, Jakobsen, A, et al. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer Treatment Res Commun 2018; 14: 7–12.
Google Scholar | Crossref | Medline26. Werner, T, Sachdev, J, Swisher, E, et al. Veliparib (ABT-888) extended-release formulations: a phase 1 study on safety, pharmacokinetics (PK), and bioavailability in patients with advanced solid tumors. J Clin Oncol 2016; 34: 2579–2579.
Google Scholar | Crossref27. Appleman, L, Beumer, J, Jiang, Y, et al. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol 2019; 84: 1289–1301.
Google Scholar | Crossref | Medline28. Pothuri, B, Brodsky, A, Sparano, J, et al. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. Cancer Chemother Pharmacol 2020; 85: 741–751.
Google Scholar | Crossref | Medline29. Puhalla, S, Beumer, J, Pahuja, S, et al. Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA + ), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol 2014; 32: 2570–2570.
Google Scholar | Crossref | Medline30. Pahuja, S, Beumer, J, Appleman, L, et al. A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). J Clin Oncol 2015; 33: 1015–1015.
Google Scholar | Crossref | Medline31. Rodler, E, Kurland, B, Griffin, M, et al. Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation–associated breast cancer. Clin Cancer Res 2016; 22: 2855–2864.
Google Scholar | Crossref | Medline32. Han, H, Diéras, V, Robson, M, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomised phase II study. Ann Oncol 2018; 29: 154–161.
Google Scholar | Crossref | Medline33. Loibl, S, O’Shaughnessy, J, Untch, M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018; 19: 497–509.
Google Scholar | Crossref | Medline34. Jagsi, R, Griffith, K, Bellon, J, et al. Concurrent veliparib With chest wall and nodal radiotherapy in patients With inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 phase I multicenter study. J Clin Oncol 2018; 36: 1317–1322.
Google Scholar | Crossref | Medline35. Wesolowski, R, Stover, D, Lustberg, M, et al. Phase I study of veliparib on an intermittent and continuous schedule in combination with carboplatin in metastatic breast cancer: a safety and [ 18F ]-fluorothymidine positron emission tomography biomarker study. Oncologist 2020; 25: e1158–e1169.
Google Scholar | Crossref | Medline36. Ramalingam, S, Blais, N, Mazieres, J, et al. Randomised, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic Non–small cell lung cancer. Clin Cancer Res 2016; 23: 1937–1944.
Google Scholar | Crossref | Medline37. Pietanza, M, Waqar, S, Krug, L, et al. Randomised, double-blind, phase II study of temozolomide in combination With either veliparib or placebo in patients With relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 2018; 36: 2386–2394.
Google Scholar | Crossref | Medline38. Owonikoko, T, Dahlberg, S, Sica, G, et al. Randomised phase II trial of cisplatin and etoposide in combination With veliparib or placebo for extensive-stage small-cell lung cancer: eCOG-ACRIN 2511 study. J Clin Oncol 2019; 37: 222–229.
Google Scholar | Crossref | Medline39. Atrafi, F, Groen, H, Byers, L, et al. A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors. Clin Cancer Res 2018; 25: 496–505.
Google Scholar | Crossref | Medline40. Clarke, J, Patel, J, Robert, F, et al. Veliparib in combination with nivolumab and platinum doublet chemotherapy (CT) in metastatic/advanced NSCLC. J Clin Oncol 2018; 36: 3061–3061.
Google Scholar | Crossref | Medline